Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy

Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass $25 billion by 2030